Halucenex is focused on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine. The company is using psychedelics to treat veterans with PTSD and anxiety at its treatment center and research facility in Nova Scotia.
In early 2021, Halucenex was acquired by Nova Scotia-based cannabis company Creso Pharma. Recently, Halucenex has been issued a Controlled Drugs and Substances Dealer’s Licence by Health Canada. Halucenx can now progress with its planned Phase-II trial testing the efficacy of psilocybin on PTSD. The licence also allows Halucenex to possess, sell, and conduct R&D activities on a range of controlled substances.
News
- Creso Pharma’s psychedelics subsidiary Halucenex receives Canadian licence approval, targets Phase II trials on PTSD (Stockhead, August 2021)
Activities
B2B
B2C
Pharmaceutical
Biotech
Clinic
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates